We are seeking an experienced and driven Sales Representative to lead Cyagen’s market expansion in Japan. This role involves managing sales activities, maintaining strong customer relationships, and executing market strategies that support our advanced gene editing and disease model services.

Cyagen is seeking a dynamic and detail-oriented International Marketing Specialist to support our global growth initiatives. In this role, you’ll help amplify our brand across international markets, drive lead generation, and support marketing activities that directly impact our global presence in the life sciences industry.

Cyagen is seeking a dynamic and strategic Business Development Manager to lead market expansion efforts in South Korea. This role focuses on driving sales growth, building lasting customer relationships, and executing market-specific strategies to enhance Cyagen’s presence and revenue in the Korean life sciences sector.

--

--

Recently, Cyagen (Suzhou) Biosciences Co., Ltd. ("Cyagen") signed a strategic cooperation agreement with Lumiere Therapeutics (Suzhou) Co., Ltd. ("Lumiere") to jointly advance the commercialization of Lumiere’s enCas12Ultra. The two parties reached a licensing agreement on the patents and technology related to the high-efficiency, low off-target gene-editing tool, enCas12Ultra.

On July 26, 2024, InnoVec's IVB103 injection received early Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), which may now proceed to the clinical trial phase.

Cyagen Biosciences (Suzhou) Inc. (“Cyagen Biosciences”) and Shanghai BaiYing Bio-Technology Co., Ltd. (“Biointron”) have signed a strategic cooperation agreement. This partnership aims to fully leverage the advantages of Cyagen Biosciences' antibody discovery platform, featuring next-generation HUGO-Ab™ Fully Humanized Antibody Mice, in combination with the strengths of Biointron's Single B Cell Screening Antibody Discovery platform for developing antigen-specific monoclonal antibodies (mAbs).

HistoWiz and Cyagen Biosciences have formed a strategic partnership to integrate automated histology with custom mouse and rat model development—offering researchers a seamless solution from model generation to tissue analysis.

ZIP Solutions (Barcelona), a 100% affiliate of Biat Group (ticker BST), and YIMA Gene, a subsidiry under Cyagen Group, are please to announce a strategic co-marketing agreement for gene therapy.